![](https://soundbioventures.com/wp-content/uploads/2024/01/Pressrelease_Breye-first-patient_jan24-720x378.png)
Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
/ • Investigating potential for an oral treatment in diabetic retinopathy• First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a ...